Grandér D, Hultcrantz R, Weiland O, Xu B, Sangfelt O, Björklund A C, Befrits R, Björkholm M, Gruber A, Kinnman N, Reichard O, Widell A, Einhorn S
Dept. of Oncology, Radiumhemmet, Stockholm, Sweden.
Scand J Gastroenterol. 1996 Jun;31(6):604-11. doi: 10.3109/00365529609009135.
The mechanism behind the antiviral action of interferon (IFN) therapy in chronic hepatitis C virus (HCV) infection is not well understood, and, furthermore, few factors have been shown to be good predictors of a favourable response to IFN treatment in chronic HCV infection.
Freshly explanted liver cells and peripheral blood mononuclear cells (PBMC) from 80 patients with chronic HCV infection were used to study the capacity of IFN to induce the enzyme 2',5'-oligoadenylate synthetase (2'5'-AS) in vitro. The HCV genotype was determined in 53 patients. The induction of 2'5'-AS was correlated to the results of IFN-alpha treatment in 36 patients.
Normalization of transaminases during IFN treatment was significantly associated with 2'5'-AS levels in liver cells cultured in the absence of IFN. A similar tendency, although not statistically significant, was found for IFN-induced levels of 2'5'-AS in liver cells. No such associations were found when PBMC were analysed. Six patients showed a sustained biochemical response. These six did not deviate significantly from the remaining patients with regard to base-line or IFN-induced levels of 2'5'-AS in liver cells or PBMC. Eradication of HCV RNA during IFN treatment did not correlate with 2'5'-AS levels in liver cells. Comparison of HCV genotype and clinical response showed that patients with genotype 3a had the most favourable outcome. No association was found between liver histology and treatment outcome.
These data imply that direct effects of IFN on liver cells are of importance for the response to IFN treatment.
干扰素(IFN)治疗慢性丙型肝炎病毒(HCV)感染的抗病毒作用机制尚未完全明确,此外,很少有因素被证明是慢性HCV感染患者对IFN治疗产生良好反应的良好预测指标。
采用80例慢性HCV感染患者新鲜分离的肝细胞和外周血单核细胞(PBMC),研究IFN体外诱导2',5'-寡腺苷酸合成酶(2'5'-AS)的能力。对53例患者进行了HCV基因型测定。将36例患者的2'5'-AS诱导情况与IFN-α治疗结果进行关联分析。
IFN治疗期间转氨酶正常化与未添加IFN培养的肝细胞中2'5'-AS水平显著相关。在肝细胞中,IFN诱导的2'5'-AS水平也有类似趋势,尽管无统计学意义。分析PBMC时未发现此类关联。6例患者出现持续生化反应。这6例患者在肝细胞或PBMC中2'5'-AS的基线水平或IFN诱导水平方面与其余患者无显著差异。IFN治疗期间HCV RNA的清除与肝细胞中2'5'-AS水平无关。比较HCV基因型与临床反应发现,3a基因型患者的治疗效果最佳。未发现肝脏组织学与治疗结果之间存在关联。
这些数据表明,IFN对肝细胞的直接作用对IFN治疗反应具有重要意义。